ORIC Pharmaceuticals, Inc.

Stocks

ORIC

US68622P1093

Market Closed - Nasdaq Other stock markets 16:00:00 2026-07-23 EDT			5-day change	1st Jan Change
10.89 ^USD	+1.30%		+1.49%	+33.13%

07-14	ORIC Pharmaceuticals Starts Phase 3 Trial of Rinzimetostat in Metastatic Prostate Cancer	MT
07-14	Oric Pharmaceuticals Initiates Himalayas-1 Global Phase 3 Trial in Patients with Mcrpc Previously Treated with Abiraterone	CI

Transcript : ORIC Pharmaceuticals, Inc. - Special Call

Published on 03/31/2026 at 10:05 pm EDT - Modified on 04/13/2026 at 07:50 pm EDT

S&P Capital IQ

Add MarketScreener to your sources

Presentation Operator Message
Operator (Operator)

Good day, and thank you for standing by. Welcome to the ORIC Pharma Update Conference Call. [Operator Instructions]. Please be advised that today's

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Add MarketScreener to your sources

Latest news about ORIC Pharmaceuticals, Inc.

07-14	ORIC Pharmaceuticals Starts Phase 3 Trial of Rinzimetostat in Metastatic Prostate Cancer	MT
07-14	Oric Pharmaceuticals Initiates Himalayas-1 Global Phase 3 Trial in Patients with Mcrpc Previously Treated with Abiraterone	CI
06-09	ORIC Pharmaceuticals, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 08:00 AM
05-04	ORIC Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-17	ORIC Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings	CI
04-01	Wall Street Set to Open Higher as Trump Says US Will Consider Ceasefire if Hormuz Strait Opened	MT
04-01	Top Premarket Decliners	MT
04-01	Wedbush Cuts Price Target on ORIC Pharmaceuticals to $17 From $20, Keeps Outperform Rating	MT
03-31	ORIC Pharmaceuticals, Inc. - Special Call
03-31	ORIC Pharmaceuticals to Launch Phase 3 Trial of Prostate Cancer Drug Candidate, Shares Falter	MT
03-31	ORIC Pharmaceuticals, Inc. Reports Selection Of Rinzimetostat RP3D In Combination With Darolutamide For Himalayas-1 Phase 3 Global Study With Dose Optimization Data Supporting Its Potential Best-In-Disease Profile	CI
03-27	Oric Pharmaceuticals Reports Combination Dose Optimization Data From Phase 1b Trial Of Rinzimetostat In Patients With Metastatic Castration Resistant Prostate Cancer	CI
03-06	Oric Pharmaceuticals reports inducement grants under Nasdaq listing rule 5635(c)(4)	RE
02-26	Oric Pharmaceuticals Insider Sold Shares Worth $702,686, According to a Recent SEC Filing	MT
02-23	ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI